

Advances in Lipoprotein (a) | Cardiology Grand Rounds

References - Knowles & Khandelwal

- Bittner, V. A., Szarek, M., Aylward, P. E., Bhatt, D. L., Diaz, R., Edelberg, J. M., Fras, Z., Goodman, S. G., Halvorsen, S., Hanotin, C., Harrington, R. A., Jukema, J. W., Loizeau, V., Moriarty, P. M., Moryusef, A., Pordy, R., Roe, M. T., Sinnaeve, P., Tsimikas, S., Vogel, R., ... ODYSSEY OUTCOMES Committees and Investigators (2020). Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. *Journal of the American College of Cardiology*, 75(2), 133–144.
<https://doi.org/10.1016/j.jacc.2019.10.057>
- Cegla, J., Neely, R. D. G., France, M., Ferns, G., Byrne, C. D., Halcox, J., Datta, D., Capps, N., Shoulders, C., Qureshi, N., Rees, A., Main, L., Cramb, R., Viljoen, A., Payne, J., & Soran, H. (2019). Heart UK consensus statement on Lipoprotein(a): A call to action. *Atherosclerosis*, 291, 62–70. <https://doi.org/10.1016/j.atherosclerosis.2019.10.011>
- Kaiser, Y., Daghem, M., Tzolos, E., Meah, M. N., Doris, M. K., Moss, A. J., Kwiecinski, J., Kroon, J., Nurmohamed, N. S., van der Harst, P., Adamson, P. D., Williams, M. C., Dey, D., Newby, D. E., Stroes, E. S. G., Zheng, K. H., & Dweck, M. R. (2022). Association of lipoprotein(a) with atherosclerotic plaque progression. *Journal of the American College of Cardiology*, 79(3), 223–233. <https://doi.org/10.1016/j.jacc.2021.10.044>
- Kamstrup, P. R. (2009). Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. *JAMA*, 301(22), 2331. <https://doi.org/10.1001/jama.2009.801>
- Kato, A., Kinoshita, D., Nagata, T., Asakura, K., Katamine, M., Katsura, A., Hashimoto, T., Minami, Y., & Ako, J. (2022). Lipoprotein (a) levels and vulnerable characteristics in nonculprit plaque in patients with acute coronary syndrome. *IJC Heart & Vasculature*, 43, 101120. <https://doi.org/10.1016/j.ijcha.2022.101120>
- Kronenberg, F. (2016). Human genetics and the causal role of lipoprotein(a) for various diseases. *Cardiovascular Drugs and Therapy*, 30(1), 87–100.
<https://doi.org/10.1007/s10557-016-6648-3>

Kronenberg, F., Mora, S., Stroes, E. S. G., Ference, B. A., Arsenault, B. J., Berglund, L., Dweck, M. R., Koschinsky, M., Lambert, G., Mach, F., McNeal, C. J., Moriarty, P. M., Natarajan, P., Nordestgaard, B. G., Parhofer, K. G., Virani, S. S., von Eckardstein, A., Watts, G. F., Stock, J. K., Ray, K. K., ... Catapano, A. L. (2022). Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. *European heart journal*, 43(39), 3925–3946.

<https://doi.org/10.1093/eurheartj/ehac361>

Kronenberg, F., & Tsimikas, S. (2019). The challenges of measuring Lp(a): A fight against Hydra?. *Atherosclerosis*, 289, 181–183.

<https://doi.org/10.1016/j.atherosclerosis.2019.08.019>

Langsted, A., Kamstrup, P. R., Benn, M., Tybjaerg-Hansen, A., & Nordestgaard, B. G. (2016). High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: A prospective cohort study. *The Lancet Diabetes & Endocrinology*, 4(7), 577–587.

[https://doi.org/10.1016/s2213-8587\(16\)30042-0](https://doi.org/10.1016/s2213-8587(16)30042-0)

Nordestgaard, B. G. (2017). A test in context: Lipid profile, fasting versus nonfasting. *Journal of the American College of Cardiology*, 70(13), 1637–1646.

<https://doi.org/10.1016/j.jacc.2017.08.006>

Nordestgaard, B. G., Chapman, M. J., Ray, K., Borén, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., Lesnik, P., Masana, L., Reiner, Z., Taskinen, M.-R., Tokgözoğlu, L., & Tybjaerg-Hansen, A. (2010). Lipoprotein(a) as a cardiovascular risk factor: Current status. *European Heart Journal*, 31(23), 2844–2853. <https://doi.org/10.1093/eurheartj/ehq386>

O'Donoghue, M. L., Morrow, D. A., Tsimikas, S., Sloan, S., Ren, A. F., Hoffman, E. B., Desai, N. R., Solomon, S. D., Domanski, M., Arai, K., Chiuve, S. E., Cannon, C. P., Sacks, F. M., & Sabatine, M. S. (2014). Lipoprotein(a) for risk assessment in patients with established coronary artery disease. *Journal of the American College of Cardiology*, 63(6), 520–527.

<https://doi.org/10.1016/j.jacc.2013.09.042>

Pearson, G. J., Thanassoulis, G., Anderson, T. J., Barry, A. R., Couture, P., Dayan, N., Francis, G. A., Genest, J., Grégoire, J., Grover, S. A., Gupta, M., Hegele, R. A., Lau, D., Leiter, L. A.,

- Leung, A. A., Lonn, E., Mancini, G. B. J., Manjoo, P., McPherson, R., Ngui, D., ... Wray, W. (2021). 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. *The Canadian journal of cardiology*, 37(8), 1129–1150. <https://doi.org/10.1016/j.cjca.2021.03.016>
- Schmidt, K., Noureen, A., Kronenberg, F., & Utermann, G. (2016). Structure, function, and genetics of lipoprotein (a). *Journal of Lipid Research*, 57(8), 1339–1359. <https://doi.org/10.1194/jlr.r067314>
- Suwa, S., Ogita, M., Miyauchi, K., Sonoda, T., Konishi, H., Tsuboi, S., Wada, H., Naito, R., Dohi, T., Kasai, T., Okazaki, S., Isoda, K., & Daida, H. (2017). Impact of Lipoprotein (a) on Long-Term Outcomes in Patients with Coronary Artery Disease Treated with Statin After a First Percutaneous Coronary Intervention. *Journal of atherosclerosis and thrombosis*, 24(11), 1125–1131. <https://doi.org/10.5551/jat.38794>
- Tsimikas S. (2017). A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. *Journal of the American College of Cardiology*, 69(6), 692–711. <https://doi.org/10.1016/j.jacc.2016.11.042>
- Tsimikas, S., Fazio, S., Ferdinand, K. C., Ginsberg, H. N., Koschinsky, M. L., Marcovina, S. M., Moriarty, P. M., Rader, D. J., Remaley, A. T., Reyes-Soffer, G., Santos, R. D., Thanassoulis, G., Witztum, J. L., Danthi, S., Olive, M., & Liu, L. (2018). NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. *Journal of the American College of Cardiology*, 71(2), 177–192. <https://doi.org/10.1016/j.jacc.2017.11.014>
- Wilson, D. P., Jacobson, T. A., Jones, P. H., Koschinsky, M. L., McNeal, C. J., Nordestgaard, B. G., & Orringer, C. E. (2019). Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. *Journal of clinical lipidology*, 13(3), 374–392. <https://doi.org/10.1016/j.jacl.2019.04.010>
- Yoon, Y. H., Ahn, J. M., Kang, D. Y., Lee, P. H., Kang, S. J., Park, D. W., Lee, S. W., Kim, Y. H., Han, K. H., Lee, C. W., Park, S. W., & Park, S. J. (2021). Association of Lipoprotein(a) With Recurrent Ischemic Events Following Percutaneous Coronary Intervention. *JACC*.

Cardiovascular interventions, 14(18), 2059–2068.

<https://doi.org/10.1016/j.jcin.2021.07.042>